Biomarkers in sepsis
By Mervyn Singer. Current opinion in pulmonary medicine, 2013
668 citations recorded by the source corpus.
Purpose of review This review discusses the current developments in biomarkers for sepsis. Recent findings With quantum leaps in technology, an array of biomarkers will become available within the next decade as point-of-care tools that will likely revolutionize the management of sepsis. These markers will facilitate early and accurate diagnosis, faster recognition of impending organ dysfunction, optimal selection and titration of appropriate therapies, and more reliable prognostication of risk and outcome. These diagnostics will also enable an improved characterization of the biological phenotype underlying sepsis and thus a better appreciation of the condition. Summary The potential for novel biomarkers in sepsis will need to be properly realized with considerable funding, academic–industry collaborations, appropriate investigations and validation in heterogenous populations, but these developments do hold the capacity to transform patient care and outcomes.
Subfields: Epidemiology, Immunology
View Paper: https://www.semanticscholar.org/paper/8726629f7ed8b09fa718d08685d0c41cb6514938
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Immunology
Citations in the corpus
- The Pathogenesis of Sepsis (2011, background): “A kinetic study of high mobility group box 1 demonstrated that it remained persistently elevated in the plasma compared with cytokines such as IL-6, IL-8, and TNF, emphasizing this biomarker’s high clinical relevance (90, 92, 116).”
- Assessment of Diagnostic and Prognostic Role of Copeptin in the Clinical Setting of Sepsis (2016, background): “The use of biomarkers may be useful in the detection of infection and in the management of the septic patient; despite the fact that more than 100molecules have been evaluated in sepsis [6], an ideal biomarker, that is to say a molecule which, at the same time, allows early diagnosis, risk stratific”